Emcure Pharmaceuticals is planning to garner about Rs 600 crore through an initial public offering (IPO). In this regard, Blackstone backed Pune-based pharma company has filed its draft prospectus with SEBI to offer upto 29 per cent stake in the company.
DSP Merrill Lynch, IDFC Capital and Morgan Stanley India Company have been appointed as book running lead managers to the issue.
Emcure Pharmaceuticals develops, manufactures and markets a broad range of pharmaceutical products in major therapeutic areas including blood related, cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients products.
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: